The earnings call reflects a strong performance by Harmony Biosciences with significant revenue growth and advancements in their clinical pipeline. The company has a robust pipeline and financial health, although there are some concerns about trade inventory reductions and potential expenses. Overall, the positive aspects significantly outweigh the challenges.

Company Guidance

During the Harmony Biosciences Second Quarter 2025 Financial Results Conference Call, the company provided several key metrics and forward-looking statements. Harmony reported $200.5 million in net revenue for Q2 2025, marking a 16% year-over-year increase, primarily driven by the continued growth of WAKIX in the narcolepsy market. The company added approximately 400 average patients during the quarter and reaffirmed their full-year revenue guidance of $820 million to $860 million. Harmony anticipates achieving $1 billion in annual revenue from WAKIX alone. The call also highlighted the advancement of their late-stage pipeline, including the upcoming Phase III trial data for ZYN002 in Fragile X syndrome, expected later in Q3 2025. The company maintains a strong cash position with over $670 million, providing flexibility for strategic business development. Harmony is actively preparing for further growth, with up to six Phase III trials expected by year-end and plans to launch new products or indications annually over the next several years.

Strong Revenue Growth

Harmony Biosciences reported $200.5 million in net revenue for the second quarter, representing a 16% increase year-over-year.

WAKIX Performance

WAKIX delivered $200.5 million in net sales for the quarter, with a 16% year-over-year growth and an addition of approximately 400 average patients.

Advancements in Clinical Pipeline

The Phase III registrational trial for ZYN002 in Fragile X syndrome completed enrollment, with top-line data expected later in the quarter.

Robust Pipeline and Future Prospects

Harmony has a robust pipeline with 8 innovative assets across 13 development programs, including up to 6 Phase III trials by the end of the year.

Positive Financial Health

Non-GAAP adjusted net income for the quarter was $53.8 million, indicating sustained profitability and financial stability.

Harmony Biosciences Holdings (HRMY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HRMY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2025 (Q3)	0.74 / -	0.79	―	―	―
Jul 31, 2025	2025 (Q2)	0.70 / 0.68	0.2	240.00% (+0.48)	―	―
May 06, 2025	2025 (Q1)	0.61 / 0.78	0.67	16.42% (+0.11)
Feb 25, 2025	2024 (Q4)	0.73 / 0.85	0.45	88.89% (+0.40)
Oct 29, 2024	2024 (Q3)	0.67 / 0.79	0.63	25.40% (+0.16)
Aug 06, 2024	2024 (Q2)	>-0.01 / 0.20	0.56	-64.29% (-0.36)
Apr 30, 2024	2024 (Q1)	0.60 / 0.67	0.48	39.58% (+0.19)
Feb 22, 2024	2023 (Q4)	0.72 / 0.45	0.79	-43.04% (-0.34)
Oct 31, 2023	2023 (Q3)	0.67 / 0.63	1.44	-56.25% (-0.81)
Aug 01, 2023	2023 (Q2)	0.61 / 0.56	0.39	43.59% (+0.17)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

HRMY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$35.48	$35.18	-0.85%
May 06, 2025	$29.96	$32.05	+6.98%
Feb 25, 2025	$34.18	$36.97	+8.16%
Oct 29, 2024	$35.75	$41.49	+16.06%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Harmony Biosciences Holdings (HRMY) report earnings?

Harmony Biosciences Holdings (HRMY) is schdueled to report earning on Nov 04, 2025, Before Open (Confirmed).

What is Harmony Biosciences Holdings (HRMY) earnings time?

Harmony Biosciences Holdings (HRMY) earnings time is at Nov 04, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is HRMY EPS forecast?

HRMY EPS forecast for the fiscal quarter 2025 (Q3) is 0.74.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing